FFTY
Innovator IBD 50 ETF
The Innovator IBD 50 Fund is an active fund that takes the constituents of the IBD 50 Index and reweights them from price-weighted to a proprietary method based on specific fundamental and technical indicators. It holds US-listed stocks and ADRs.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 72.6 M
ASSETS UNDER MGMT
80 bp
EXPENSES
Fund Basics
| Inception date | Apr 08, 2015 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| FAMOUS DAVE'S OF AMERICA | 3.6 % |
| HINGE HEALTH INC-A | 3.6 % |
| TG THERAPEUTICS INC | 3.6 % |
| WISDOMTREE INVESTMENTS INC | 3.5 % |
| KINIKSA PHARMACEUTICALS LTD. CLASS A | 3.5 % |
| TRAVERE THERAPEUTICS, INC. | 3.4 % |
| NATERA INC | 3.4 % |
| AURA MINERALS INC | 3.4 % |
| ETON PHARMACEUTICALS, INC. | 3.3 % |
| ERO COPPER CORP. | 3.1 % |
Constituent Breakdown
| Number of holdings | 49 |
| Herfindahl-Hirschman Index | 269 |
| Wgt avg mkt cap (mns) | $44,449 |
| Large cap (>$10bn) | 38.1% |
| Mid cap ($2-10bn) | 48.9% |
| Small cap (<$2bn) | 9.8% |
| Developed mkts. | 95.7% |
| Emerging mkts. | 1.1% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 81.2 % |
 |
CANADA | 5.1 % |
 |
BERMUDA | 3.5 % |
 |
JAPAN | 2.9 % |
 |
SOUTH AFRICA | 2.3 % |
 |
NETHERLANDS | 1.0 % |
Historical Performance
Standardized Performance (as of 08/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 4.1% | 3.7% | 18.1% | 14.9% | -5.8% | 4.6% | -- | 3.3% |
| Dividend Yield | 0.0% | 0.0% | 0.5% | 0.6% | 0.8% | 0.5% | -- | 0.4% |
| Total Returns | 4.1% | 3.7% | 18.6% | 15.5% | -5.0% | 5.0% | -- | 3.7% | Ann. Volatility | 37.3% | 36.2% | 34.1% | 30.8% | 29.8% | 27.9% | -- | 27.0% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 2.04 | 52% |
| MSCI EAFE | 1.51 | 42% |
| MSCI Emg Mkts | 1.07 | 54% |
Liquidity Measures
| Avg. volume (000) | 19 |
| ADV traded (mns) | $1 |
| Turnover | 1.0% |
| Avg. Bid/Ask (% of price) | 0.22% |
Technical Indicators
| 30d moving avg. (EMA) | $38.16 |
| Relative strength (RSI) | 47 |
| MACD/Signal | -0.61/-0.77 |
| Bollinger Bands (Upper/Lower) | $38.48/$36.33 |
| Short interest (% of AUM) | 1.3% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. FFTY |
Expenses vs. FFTY |
ALTAR Score™ vs. FFTY |
|---|---|---|---|---|
| BOUT | Innovator IBD Breakout Opportunities ETF | 30.6% | +1 bp | +3.4% |
| FMTM | MarketDesk Focused U.S. Momentum ETF | 15.1% | -35 bp | +4.4% |
| HELX | Franklin Genomic Advancements ETF | 11.5% | -30 bp | -1.8% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 10.5% | -24 bp | +0.6% |
| MMSC | First Trust Multi-Manager Small Cap Opportunities ETF | 10.3% | +15 bp | -0.7% |
| EKG | First Trust Nasdaq Lux Digital Health Solutions ETF | 10.2% | -15 bp | 0.0% |
Risk and Returns: FFTY vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 9/7/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
0.8%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 1,408 funds in the US Equity category with an average
ALTAR Score™ of 5.2% and a standard deviation
of 2.0%. FFTY's ALTAR Score™ is approximately -2.2 standard
deviations above the category average. This places FFTY in the 1st percentile
among funds in the category.
Sell-Side Consensus
$33.81
PRICE TARGET
-6.8%
UPSIDE